Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Lacerating Aortic Leaflets Can Prevent TAVR Obstructions

By HospiMedica International staff writers
Posted on 17 Apr 2018
A new study describes how an innovative surgical technique can help prevent coronary artery obstruction during transcatheter aortic valve replacement (TAVR).

Developed by researchers at the U.S. More...
National Heart, Lung and Blood Institute (NHLBI; Bethesda, MD, USA), Emory University Hospital (Atlanta, GA, USA), and other institutions, the bioprosthetic aortic scallop intentional laceration to prevent coronary artery obstruction (BASILICA) technique involves cutting the pericardial leaflets using catheter electrosurgery to traverse and split the aortic leaflet down the center line. TAVR is then performed as usual, followed by leaflet splaying.

The researchers first tested the procedure in a swine model, with TAVR followed by lacerating and splaying of bovine pericardial leaflets. The results showed that BASILICA was successful in the pigs, in both left and right cusps; necropsy revealed full-length lacerations with no collateral thermal injury. The procedure was then offered (on a compassionate basis) to seven patients with high risk of coronary obstruction who were ineligible for surgical aortic valve replacement (SAVR). All patients underwent successful TAVR, with no coronary obstruction, stroke, or major complications. The study was published on April 2, 2018, in the Journal of the American College of Cardiology: Cardiovascular Interventions.

“In some patients whose hearts have uncommon structures, such as unusually large valve leaflets or small aortic roots, the large leaflets block the flow of blood to the coronary arteries as the new valve's scaffolding opens,” said lead author Robert Lederman, MD, of the NHLBI division of intramural research. “These patients are either not eligible for conventional TAVR, or they are at high risk for it. The previous technique of using a stent to open the coronary artery appears to have poor long-term outcomes.”

The percutaneous treatment of severe aortic valve disease using TAVR prosthetic valve replacement, without the need for open-heart surgery or cardiopulmonary bypass, is faster and less invasive than current open-heart procedures. TAVR has so far been proven effective in high-risk and inoperable patients, and could soon become the standard of care, even in moderate and low surgical risk patients.

Related Links:
U.S. National Heart, Lung and Blood Institute
Emory University Hospital



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The 3D-printed microneedle patch boosts live-virus vaccine delivery (Photo courtesy of IIS/University of Tokyo)

3D-Printed Delivery System Enhances Vaccine Delivery Via Microneedle Array Patch

The COVID-19 pandemic underscored the need for efficient, durable, and widely accessible vaccines. Conventional vaccination requires trained personnel and cold-chain logistics, which can slow mass immunization... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.